HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer[Biotin], His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.

价格	￥4900 在线订购包邮(港澳台除外)
产品编号	Z06503-100
规格	100 μg 500 μg 大单询价
数量
参考货期


咨询产品问题

产品简介图例技术背景

产品简介

Species

Human

Protein Construction

HLA-A11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer [Gly25-Thr305(HLA-A11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide] Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAGGVGK	His	Avi
N-term		C-term

Conjugate

Biotin

Purity

> 95% as determined by BisTris PAGE

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.

Expression System

E.coli

Theoretical Molecular Weight

35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M)

Apparent Molecular Weight

The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

图例

Immobilized HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer[Biotin], His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 7.7 ng/ml determined by ELISA. »

The purity of HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC »

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

技术背景

Target Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
Synonyms	MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.